Health ❯ Healthcare ❯ Patient Care

Treatment Options

Oral Medications Innovative Therapies Subcutaneous Administration Combination Therapy Cancer Treatment Cognitive Impairment Personalized Medicine Adjuvant Therapy Hormone Therapy Immunotherapy

CHMP Backs Xolremdi for WHIM Syndrome Under Exceptional Circumstances

A European Commission decision now follows, reflecting limited trial data in a rare disease that require ongoing evidence commitments.

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial

EMA Panel Backs Conditional EU Approval for Ojemda in Pediatric Low-Grade Glioma

FDA Approves First All-Oral, Fixed-Duration First-Line CLL/SLL Regimen: Calquence Plus Venetoclax

Priovant’s Brepocitinib Posts Strong Phase 2 Win in Cutaneous Sarcoidosis

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

Triple Therapy Eradicates Pancreatic Tumors in Mice in CNIO Study

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

FDA Grants Priority Review to Leqembi Autoinjector for Weekly At-Home Starting Dose

Abemaciclib Shows Early Benefit Signal in Genetically Selected High-Grade Meningioma Trial

UK Glaucoma Burden Far Higher Than Thought, Projected to Reach 1.61 Million by 2060

Cambridge Scientists Develop Blood Test to Sharpen Prostate Cancer Detection

FDA Issues Second Rejection of Atara’s EBV+ PTLD Therapy Tabelecleucel

Brazil Authorizes Leqembi for Early-Stage Alzheimer’s Treatment

FDA Grants Priority Review to Vera's Atacicept for IgA Nephropathy

FDA Grants Orphan Drug Status to Cellenkos’ CK0804 for Myelofibrosis

Zenas' Obexelimab Meets Phase 3 Goals in IgG4-Related Disease With 56% Flare Risk Cut

UK Approves First Twice-Yearly Asthma Biologic as GSK Targets 2026 Launch

Cosmo’s Clascoterone Meets Phase III Goals in Male-Pattern Baldness Trials

FDA Approves Aqvesme for Thalassemia Anemia, First U.S. Therapy for Both Patient Groups